Thelansis

Macrophage Activation Syndrome (MAS) Market Outlook Thelansis’s “Macrophage Activation Syndrome (MAS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Macrophage Activation Syndrome (MAS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

  Macrophage Activation Syndrome (MAS) Market Outlook Thelansis’s “Macrophage Activation Syndrome (MAS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Macrophage Activation Syndrome (MAS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Macrophage Activation Syndrome (MAS) Overview Macrophage activation syndrome (MAS) is a severe complication of rheumatic diseases in childhood, mainly systemic Juvenile Idiopathic Arthritis (sJIA). MAS is typically characterized by high fever, lymphadenopathy, hepatosplenomegaly, hemorrhages, and signs of liver, central nervous system, and kidney involvement, potentially leading to multiple orga...

  Macrophage activation syndrome (MAS) is a severe complication of rheumatic diseases in childhood, mainly systemic Juvenile Idiopathic Arthritis (sJIA). MAS is typically characterized by high fever, lymphadenopathy, hepatosplenomegaly, hemorrhages, and signs of liver, central nervous system, and kidney involvement, potentially leading to multiple organ failure. Laboratory abnormalities in MAS include leukopenia, thrombocytopenia, anemia, hypertransaminasemia, markedly elevated ferritin levels, and evidence of intravascular coagulation activation. MAS is generally classified among the secondary forms of hemophagocytic lymphohistiocytosis (sHLH), as it occurs in the context of rheumatic disease. MAS and HLH share numerous clinical and laboratory features, with notable differences attributable to the inflammatory background of MAS, such as higher platelet counts and fibrinogen levels compared to primary HLH (pHLH). Primary HLH is caused by mutations in genes encoding proteins invol...